Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.
Cancer 103(9):1850-5 (2005) PMID 15786422
A Phase I/II study was designed to show whether the addition of semisynthetic homoharringtonine (sHHT) would reduce the level of residual disease in patients with Ph-positive chronic myeloid leukemia who appeared to have achieved a suboptimal response to imatinib alone.
DOI: 10.1002/cncr.20975
Version: za2963e q8zaa q8zbd q8zc5 q8zd5 q8ze5 q8zfa q8zg5